Study Protocol for a Parallel-group, Double-blinded, Randomized, Controlled, Noninferiority Trial: the Effect and Safety of Hybrid Electroconvulsive Therapy (Hybrid-ECT) Compared with Routine Electroconvulsive Therapy in Patients with Depression
Overview
Authors
Affiliations
Background: Electroconvulsive therapy (ECT) is the most rapid and effective treatment for patients with depression, ECT can achieve remarkable antidepressant effects in the initial 3-4 sessions, but significant side effects limit its use. However, recent low-charge electrotherapy (LCE) studies have demonstrated antidepressant or antipsychotic effects with significantly fewer side effects. The aim of this study is to propose a novel two-step charge set strategy for ECT treatment, referred to as Hybrid-ECT, to decrease side effects by using a low charge while preserving treatment efficacy.
Methods/design: A randomized, double-blinded, standard-controlled, parallel-group design will be carried out. We plan to enroll 112 inpatients diagnosed with depression (unipolar or bipolar) and randomly assign them to conventional ECT (control group) or to Hybrid-ECT (treatment group, 3 ECT sessions followed by LCE sessions (approximately 2.8 joules per session)). We will evaluate participants across a wide variety of domains including clinical symptoms, cognitive, psychological and functional metrics. We will also perform magnetic resonance imaging (MRI) and event-related potential (ERPs) assessments during treatment to explore brain function differences between ECT and LCE.
Discussion: This research proposes a simple but completely novel ECT strategy that aims to rapidly relieve depressive symptoms and minimize side effects. The mechanism of ECT and LCE will be further discussed.
Trial Registration: Chinese Clinical Trial Registry, Number: ChiCTR1900022905 (Registration date: April 30, 2019).
Xiao K, Li X, Hu W, Li X Front Neurol. 2024; 15():1360437.
PMID: 38817548 PMC: 11137222. DOI: 10.3389/fneur.2024.1360437.
Xu S, Xie X, Yao L, Chen L, Wan Q, Chen Z Neuropsychiatr Dis Treat. 2023; 19:267-281.
PMID: 36744206 PMC: 9893845. DOI: 10.2147/NDT.S394155.
Current Knowledge of the Antidepressant Activity of Chemical Compounds from L.
Matraszek-Gawron R, Chwil M, Terlecki K, Skoczylas M Pharmaceuticals (Basel). 2023; 16(1).
PMID: 36678554 PMC: 9860663. DOI: 10.3390/ph16010058.
Zhang J, Xu S, Zeng L, Chen L, Li J, Jiang Z Front Psychiatry. 2022; 13:896018.
PMID: 35677877 PMC: 9168000. DOI: 10.3389/fpsyt.2022.896018.
Zou L, Li X, Chen Q, Lv F, Min S BMC Anesthesiol. 2022; 22(1):163.
PMID: 35619081 PMC: 9134596. DOI: 10.1186/s12871-022-01686-6.